Sailuotong治疗老年轻度认知障碍认知功能的随机双盲安慰剂对照12周II期试点试验研究方案
BACKGROUND: Mild cognitive impairment (MCI) is a syndrome characterised by a decline in cognition but relatively intact activities of daily living.…
要点
- SLT组与安慰剂组将在基线和终点比较共同主要认知终点及次要终点。
- 若试点结果阳性,将为更大样本量的确证性试验提供依据。
- 试验注册号ANZCTR ACTRN12617000371392,注册日期2017年3月10日。
核心结论
- 本研究旨在评估12周SLT治疗对老年轻度认知障碍患者认知功能的疗效,并探讨其通过脑电图、自主神经功能、脑血流和炎症等机制及安全性。
关键数值与推荐
- 共同主要认知结局为逻辑记忆故事A延迟回忆(情景记忆)、字母数字排序(知觉处理速度)、连线测验和Rey复杂图形测验(执行功能)。
- 次要结局包括脑电图活动、自主神经功能(心电图、皮肤电导和外周脉压)、脑血流(颈总动脉超声)和血清炎症细胞因子浓度。
- 分析将对分组分配设盲,主要和次要结局在基线和终点比较。
临床怎么用
- 若试点试验结果阳性,将为开展更大样本量的确证性临床试验提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mild cognitive impairment (MCI) is a syndrome characterised by a decline in cognition but relatively intact activities of daily living. People with MCI have an increased risk of developing dementia, and MCI is often referred to as a transitional stage between healthy ageing and dementia. Currently, there are no pharmaceutical therapies approved by the US Federal Drug Administration for MCI. Randomised controlled trials on the two major classes of anti-dementia pharmaceuticals, cholinesterase inhibitors and glutamate receptor antagonists, have produced poor results in MCI cohorts. There is a need to test and evaluate new and promising treatments for MCI that target multiple aspects of the syndrome's multi-faceted pathophysiology. The primary aim of this study is to evaluate the efficacy of 12 weeks of treatment with a standardised herbal formula, Sailuotong (SLT), compared to placebo, on cognition in older adults with MCI. Secondary aims are to assess SLT's mechanisms of action via electroencephalography (EEG), autonomic function, brain blood flow, and inflammation, as well as its safety in this cohort. METHODS/DESIGN: The target cohort for this trial is community-dwelling older adults over the age of 60 years who meet the National Institute of Aging-Alzheimer's Association working group core clinical criteria for MCI due to Alzheimer's disease. Eighty participants will be recruited and randomly allocated via a permuted block strategy at a 1:1 ratio to either the treatment or placebo group. The co-primary cognitive outcome measures are Logical Memory Story A delayed recall (episodic memory), Letter Number Sequencing (perceptual processing speed), and both the Trail Making Test and Rey Complex Figure Test (executive function). Secondary outcome measures are EEG activity, autonomic function (via electrocardiogram, skin conductance, and peripheral pulse pressure), brain blood flow (via common carotid artery ultrasound), and serum concentrations of inflammatory cytokines. Analyses will be performed blind to group allocation. DISCUSSION: This study is a 12-week, randomised, double-blind, placebo-controlled trial. Primary and secondary outcome measures will be compared between treatment and placebo groups at baseline and endpoint. Data from this pilot study will inform a larger, more highly powered clinical trial if the findings are positive. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12617000371392 Registered on 10 March 2017.
引用
- Steiner GZ, Bensoussan A, Liu J, et al. Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment. Trials. 2018. PMID: 30253809. doi:10.1186/s13063-018-2912-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。